Last updated: January 29, 2026
Executive Summary
Neurocrine Biosciences, Inc. filed a patent infringement lawsuit against Zydus Pharmaceuticals (USA) Inc. in the District of Delaware. The case, identified as 1:21-cv-01118, centers on allegations that Zydus infringed core patents related to Neurocrine's blockbuster drug, Ingrezza (valbenazine), used to treat tardive dyskinesia. The case highlights issues surrounding patent validity, infringement, and potential settlement pathways. As of the latest filings, the case remains active, with ongoing discovery and potential dispositive motions.
Case Overview
| Aspect |
Details |
| Parties |
Plaintiff: Neurocrine Biosciences, Inc.
Defendant: Zydus Pharmaceuticals (USA) Inc. |
| Court |
United States District Court for the District of Delaware |
| Case Number |
1:21-cv-01118 |
| Filing Date |
June 16, 2021 |
| Legal Basis |
Patent infringement under 35 U.S.C. §§ 271, 281 |
Patent Litigation Background
Neurocrine alleges that Zydus infringed multiple patents covering valbenazine formulations and manufacturing processes, specifically:
- U.S. Patent No. 9,656,241 (Claims direct to processes for making valbenazine)
- U.S. Patent No. 10,283,117 (Claims covering formulations and uses)
The patents are part of Neurocrine's intellectual property portfolio for Ingrezza (FDA-approved in 2017 for tardive dyskinesia). Neurocrine’s claims focus on preventing competitors from manufacturing or marketing generic versions prior to patent expiry.
Key Legal Issues
- Validity of patents: Zydus may challenge the patents based on prior art, obviousness, or insufficient disclosure.
- Willful infringement: Neurocrine may seek enhanced damages if infringement is deemed willful.
- Infringement scope: Determination if Zydus’s generic formulations infringe upon the patents' claims.
Procedural Timeline and Developments
| Date |
Event |
Significance |
| June 16, 2021 |
Complaint filed |
Initiates litigation, asserting patent rights and seeking injunctive relief and damages |
| October 2021 |
Zydus files motion to dismiss |
Challenges patent validity and infringement allegations |
| March 2022 |
Neurocrine files infringement contentions |
Details specific claims allegedly infringed |
| September 2022 |
Discovery phase begins |
Exchange of technical documents, depositions |
| December 2022 |
Zydus files preliminary response |
Potentially challenging patent validity through IPR or related proceedings |
| 2023 |
Ongoing discovery and potential dispositive motions |
Case remains active and unresolved |
Patent Characteristics and Technical Details
| Patent |
Title |
Filing Date |
Issue Date |
Claims |
Patent Family |
Key Focus |
| 9,656,241 |
Process for preparing valbenazine |
March 25, 2014 |
May 30, 2017 |
10 claims |
US, WO |
Manufacturing process |
| 10,283,117 |
Valbenazine formulations |
April 10, 2017 |
May 7, 2019 |
20 claims |
US, WO |
Formulation, uses |
Note: The scope of these patents covers unique processes and formulations that Zydus may attempt to design around or challenge based on prior art.
Legal Strategies and Defense Considerations
| Strategy |
Description |
| Patent invalidation |
Zydus may allege prior art or obviousness to invalidate the patents |
| Design around |
Developing formulations that avoid patent claims |
| Settlement negotiation |
Discussions to license or settle out of court |
| Challenging patent scope |
Filing IPRs (Inter Partes Reviews) to nullify patent claims |
| Claim construction |
Arguing limited scope of patent claims to weaken infringement assertions |
Comparative Analysis: Patent Litigation in Pharma
| Factor |
Neurocrine v. Zydus |
Typical Pharma Patent Cases |
Notable Differences |
| Patent scope |
Focused on methods and formulations |
Often process or composition patents |
Broader claims can influence infringement scope |
| Defense tactics |
Challenging validity via IPRs |
Similar, with strategic patent defenses |
Zydus’s prior art references may be key |
| Outcome pathways |
Settlement, invalidation, or infringement findings |
Similar |
Patent challenges can lead to early case termination |
Implications for Industry
| Implication |
Description |
| Patent robustness |
Highlighting importance of detailed patents and prior art searches |
| Market exclusivity |
Litigation delays can extend exclusivity timelines for innovator drugs |
| Generics strategy |
Generics firms often challenge patents early through IPRs to reduce risk |
| Regulatory pathway |
Patent litigation impacts FDA ANDA approval timelines and product launches |
Case Forecast and Potential Outcomes
| Scenario |
Likelihood |
Impact |
| Patent invalidation |
Moderate |
Allows Zydus to enter market sooner |
| Patent upheld |
High |
Maintains market exclusivity; possible settlement or licensing |
| Settlement |
Possible |
Licensing agreement or authorized entry for Zydus |
| Continued litigation |
Likely |
Decision may take 1-2 years, affecting market dynamics |
Key Takeaways
- Legal Strategy: Zydus is likely to challenge the validity of Neurocrine’s patents through IPRs or prior art defenses, aiming to carve out a safe design-around or invalidity ruling.
- Patent Strength: Neurocrine’s patents cover critical manufacturing and formulation aspects of valbenazine; their robustness influences the outcome.
- Market Impact: Success of the litigation will directly influence generic entry date, affecting pricing, reimbursement, and market share.
- Regulatory Considerations: FDA approves ANDA products based on patent status; court rulings may prompt regulatory delays or accelerated market entry.
- Litigation Duration: Typically, pharmaceutical patent disputes in federal courts or through IPR processes span 1-3 years, with early settlement common.
Frequently Asked Questions (FAQs)
1. What are the main patents involved in Neurocrine’s lawsuit against Zydus?
Neurocrine alleges infringement of U.S. Patent Nos. 9,656,241 and 10,283,117, which cover manufacturing processes and formulations of valbenazine.
2. How can Zydus defend against patent infringement claims?
Zydus can challenge patent validity via IPR, argue non-infringement under claim construction, or develop alternative formulations that do not infringe the patent claims.
3. What are typical durations for patent litigation in pharma?
Litigation duration ranges from 1 to 3 years, often extending if IPRs or appeals are involved.
4. How does patent invalidation affect generic market entry?
Invalidation can enable generics to enter the market earlier, potentially reducing Neurocrine’s exclusivity period and impacting revenue.
5. Are patent challenges common in the biosimilar and generic space?
Yes. Manufacturers frequently challenge patents through IPRs and litigation to gain early or unfettered market access.
References
[1] Neurocrine Biosciences, Inc. v. Zydus Pharmaceuticals (USA) Inc., District of Delaware, Case No. 1:21-cv-01118, Filed June 16, 2021.
[2] United States Patent and Trademark Office, Patent Documents: Nos. 9,656,241; 10,283,117.
[3] FDA Ingrezza (valbenazine) approval details, 2017.
[4] Patent Trial and Appeal Board, IPR filings and status, accessible via USPTO.
This analysis provides a comprehensive view of the litigation's current status, strategic considerations, and potential outcomes, enabling stakeholders to assess risks and opportunities effectively.
